Drug Profile
Research programme: ceramide analogues - BioLineRx
Alternative Names: BL-4060Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Hadassah Medical Organization; Hebrew University of Jerusalem
- Developer BioLineRx
- Class Ceramides; Small molecules
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Israel
- 19 Nov 2007 Preclinical trials in Cancer in Israel (unspecified route)